Mirroring/vcrpy
1
0
Fork 0
mirror of https://github.com/kevin1024/vcrpy.git synced 2025-12-08 16:53:23 +00:00
Code Releases Activity

added skip decorator for python2

Browse Source
This commit is contained in:
Rishab Malik
2019-06-28 13:03:55 -04:00
parent 95c7898b65
commit 6c877a1749
1 changed files with 23 additions and 40 deletions
Download Patch File Download Diff File Expand all files Collapse all files

63
tests/unit/test_response.py
View File

@@ -1,5 +1,8 @@
# coding: UTF-8
import io
import unittest
import six
from vcr.stubs import VCRHTTPResponse
@@ -70,6 +73,7 @@ def test_response_headers_should_have_correct_values():
assert response.headers.get('date') == "Fri, 24 Oct 2014 18:35:37 GMT"
@unittest.skipIf(six.PY2, "Regression test for Python3 only")
def test_response_parses_correctly_and_fp_attribute_error_is_not_thrown():
"""
Regression test for https://github.com/kevin1024/vcrpy/issues/440
@@ -90,46 +94,25 @@ def test_response_parses_correctly_and_fp_attribute_error_is_not_thrown():
"content-type": ["text/html; charset=utf-8"],
},
"body": {
"string": b"\nPMID- 19416910\nOWN - NLM\nSTAT- MEDLINE\nDA - 20090513\nDCOM- 20090622\nLR - "
b"20141209\nIS - 1091-6490 (Electronic)\nIS - 0027-8424 (Linking)\nVI - 106\nIP - "
b"19\nDP - 2009 May 12\nTI - Genetic dissection of histone deacetylase requirement in "
b"tumor cells.\nPG - 7751-5\nLID - 10.1073/pnas.0903139106 [doi]\nAB - Histone "
b"deacetylase inhibitors (HDACi) represent a new group of drugs currently\n being "
b"tested in a wide variety of clinical applications. They are especially\n effective "
b"in preclinical models of cancer where they show antiproliferative\n action in many "
b"different types of cancer cells. Recently, the first HDACi was\n approved for the "
b"treatment of cutaneous T cell lymphomas. Most HDACi currently in\n clinical "
b"development act by unspecifically interfering with the enzymatic\n activity of all "
b"class I HDACs (HDAC1, 2, 3, and 8), and it is widely believed\n that the development "
b"of isoform-specific HDACi could lead to better therapeutic\n efficacy. The "
b"contribution of the individual class I HDACs to different disease\n states, however, "
b"has so far not been fully elucidated. Here, we use a genetic\n approach to dissect "
b"the involvement of the different class I HDACs in tumor\n cells. We show that "
b"deletion of a single HDAC is not sufficient to induce cell\n death, but that HDAC1 "
b"and 2 play redundant and essential roles in tumor cell\n survival. Their deletion "
b"leads to nuclear bridging, nuclear fragmentation, and\n mitotic catastrophe, "
b"mirroring the effects of HDACi on cancer cells. These\n findings suggest that "
b"pharmacological inhibition of HDAC1 and 2 may be sufficient\n for anticancer "
b"activity, providing an experimental framework for the development \n of "
b"isoform-specific HDAC inhibitors.\nFAU - Haberland, Michael\nAU - Haberland M\nAD - "
b"Department of Molecular Biology, University of Texas Southwestern Medical Center,"
b"\n 5323 Harry Hines Boulevard, Dallas, TX 75390-9148, USA.\nFAU - Johnson, "
b"Aaron\nAU - Johnson A\nFAU - Mokalled, Mayssa H\nAU - Mokalled MH\nFAU - Montgomery, "
b"Rusty L\nAU - Montgomery RL\nFAU - Olson, Eric N\nAU - Olson EN\nLA - eng\nPT - "
b"Journal Article\nPT - Research Support, N.I.H., Extramural\nPT - Research Support, "
b"Non-U.S. Gov't\nDEP - 20090429\nPL - United States\nTA - Proc Natl Acad Sci U S A\nJT "
b"- Proceedings of the National Academy of Sciences of the United States of America\nJID - "
b"7505876\nRN - 0 (Antineoplastic Agents)\nRN - 0 (Histone Deacetylase Inhibitors)\nRN - "
b"0 (Protein Isoforms)\nRN - EC 3.5.1.98 (Histone Deacetylases)\nSB - IM\nMH - "
b"Animals\nMH - Antineoplastic Agents/pharmacology\nMH - Cell Death\nMH - Cell Line, "
b"Tumor\nMH - Cell Survival\nMH - Gene Expression Regulation, Enzymologic\nMH - Gene "
b"Expression Regulation, Neoplastic\nMH - Histone Deacetylase Inhibitors\nMH - Histone "
b"Deacetylases/*genetics/*physiology\nMH - Humans\nMH - Mice\nMH - Mice, Nude\nMH - "
b"Models, Genetic\nMH - Neoplasm Transplantation\nMH - Neoplasms/metabolism\nMH - "
b"Protein Isoforms\nPMC - PMC2683118\nOID - NLM: PMC2683118\nEDAT- 2009/05/07 09:00\nMHDA- "
b"2009/06/23 09:00\nCRDT- 2009/05/07 09:00\nAID - 0903139106 [pii]\nAID - "
b"10.1073/pnas.0903139106 [doi]\nPST - ppublish\nSO - Proc Natl Acad Sci U S A. 2009 May "
b"12;106(19):7751-5. doi:\n 10.1073/pnas.0903139106. Epub 2009 Apr 29.\n "
"string": b"\nPMID- 19416910\nOWN - NLM\nSTAT- MEDLINE\nDA - 20090513\nDCOM- "
b"20090622\nLR - "
b"20141209\nIS - 1091-6490 (Electronic)\nIS - 0027-8424 (Linking)\nVI - "
b"106\nIP - "
b"19\nDP - 2009 May 12\nTI - Genetic dissection of histone deacetylase "
b"requirement in "
b"tumor cells.\nPG - 7751-5\nLID - 10.1073/pnas.0903139106 [doi]\nAB - "
b"Histone "
b"deacetylase inhibitors (HDACi) represent a new group of drugs currently\n "
b" being "
b"tested in a wide variety of clinical applications. They are especially\n "
b" effective "
b"in preclinical models of cancer where they show antiproliferative\n "
b"action in many "
b"different types of cancer cells. Recently, the first HDACi was\n "
b"approved for the "
b"treatment of cutaneous T cell lymphomas. Most HDACi currently in\n "
b"clinical "
}
}
vcr_response = VCRHTTPResponse(recorded_response)